Reset all filters

Krystallenia Alexandraki

Greece
Associate Professor
Date | Session | Role

4 March | PG – Session D | Speaker
Discipline
Endocrinology
Institution
National and Kapodistrian University of Athens
Position
Associate Professor in Endocrinology, Athens Medical School
Main Interest
  • Neuroendocrinology
  • Adrenal
  • Thyroid Cancer
Receipt of grants/research support: Recordati, Ipsen Receipt of honoraria or consultation fees: Recordati, Ipsen Participation in a company sponsored speaker’s bureau: Recordati, Novartis Other support (please specify): Travel Grant support (Recordati, Ipsen, Unpharma)

Hussein Almeamar

Ireland
MBChB, MSc, MRCP (UK)
Date | Session | Role

4 March | PG – Session C | Speaker
Discipline
Endocrinology
Institution
St. Vincent's University Hospital Dublin
Position
Consultant Neuroendocrine Tumours Physician
Main Interest
  • Biological markers as predictors of response to somatostatin analogue and PRRT

Simona Barbi

Italy
Date | Session | Role

5 March | Session 4B | Speaker
Discipline
Patient / Patient Advocate
Institution
INCA - International Neuroendocrine Cancer Alliance / NET Italy ETS
Position
Member of INCA Board / Net Italy ETS President
Main Interest
  • Detlef Klaus Bartsch

Detlef Bartsch

Germany
Dr. med.
Date | Session | Role

5 March | Session 2A | Moderator
Discipline
Surgery
Institution
Dept. Visceral-, Thoracic- and Vascular Surgery Philipps-University Marburg
Position
Chairman
Main Interest
  • Surgery of small intestine NEN and pNEN
  • Surgery of anaplastic thyroid cancer

Ivan Borbath

Belgium
Prof.
Date | Session | Role

4 March | PG – Session C | Moderator
Discipline
Gastroenterology
Institution
Cliniques Universitaires Saint-Luc (UCLouvain)
Position
Chef de Clinique
Main Interest
  • Clinical research in pancreatic adenocarcinoma, in biliary tract cancer, in hepatocellular carcinoma, in NET
  • Former lead of the ENETS registry, current co-lead of the belgian registry "DNET"

Tessa Brabander

Netherlands
MD, PhD
Date | Session | Role

6 March | Session 6A | Moderator & Speaker
Discipline
Nuclear Medicine
Institution
Erasmus MC
Position
Nuclear Medicine Physician
Main Interest
  • Peptide receptor radionuclide therapy
  • Functional imaging
Receipt of grants/research support: Novartis Receipt of speaker fees: Novartis Everything paid to the institute.

Jaume Capdevila

Spain
MD, PhD
Date | Session | Role

5 March | Session 3A | Speaker
Discipline
Oncology
Institution
Vall Hebron University Hospital and Vall Hebron Institute of Oncology Barcelona
Position
Senior Medical Oncologist (Vall d’Hebron University Hospital) / Senior Clinical and Translational Researcher (Vall d’Hebron Institute of Oncology)
Main Interest
Personal conflicts of interest: Scientific consultancy role (speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Hudchmed, ITM, Merck Serono, Esteve, Advanz, Pharmamar. Research support : Research grants from Novartis, Pfizer, Astrazeneca, Advanced Accelerator Applications, Eisai, Amgen, Bayer, Roche, Gilead, ITM. Leadership roles: Chair of the Spanish Task Force for Neuroendocrine and Endocrine Tumors Group (GETNE).
  • Martyn Caplin

Martyn Caplin

United Kingdom
Professor
Date | Session | Role

5 March | Session 4A | Moderator
Discipline
Gastroenterology
Institution
Royal Free Hospital London
Position
Professor of Gastroenterology and Neuroendocrine Cancer
Main Interest
  • Translational Neuroendocrine Tumour Research - mesenetric fibrosis/desmoplasia
  • Peptide receptor expression in NETs
  • Peptide Receptor Radioligand Therapy
Research funding: Ipsen and Novartis Speaker and Advisory Board Honoraria, Ipsen, Novartis, Chiasma, Esteve and INCA

Justo P. Castaño

Spain
Bs, MSc, PhD
Date | Session | Role

4 March | BS – Session 2 & 3 | Moderator

5 March | Poster Stage 2 | Moderator
Discipline
Tumor & Cell Biology
Institution
Maimonides Biomedical Research Institute of Cordoba (IMIBIC) / University of Cordoba
Position
Professor and PI
Main Interest
  • Deciphering the role of splicing and RNA biology in Pancreatic, GI and Lung NETs
  • Somatostatin and its receptors in NETs
I have the following potential conflict(s) of interest to report: Receipt of grants/research supports: IPSEN Receipt of honoraria or consultation fees: Endocrine Oncology Editor in Chief (Bioscientifica) Travel/meeting attendance support:IPSEN, ADACAP-Novartis, Esteve

Paloma Cejas

United States of America
PhD
Date | Session | Role

4 March | BS – Session 3 | Speaker
Discipline
Oncology
Institution
Dana-Farber Cancer Institute
Position
Associate Director, Center for Functional Cancer Epigenetics
Main Interest
  • Neuroendocrine tumors
  • Epigenetic and multiomic analysis to investigate clinical samples at a single cell and spatial resolution
  • Translational research, biomarker identification

David Chan

Australia 
MBBS PhD
Date | Session | Role

5 March | Session 4B | Speaker
Discipline
Oncology
Institution
Faculty of Medicine and Health, University of Sydney
Position
Senior lecturer
Main Interest
  • PET scans as biomarkers in NET
  • NET clinical trials
  • Systematic reviews/meta-analyses
I have the following potential conflicts of interest to declare: Receipt of grants/research support - none Receipt of honoraria or consultation fees - Novartis, Ipsen, Camurus Participation in a company sponsored speaker's bureau - none Stock shareholder: None Spouse/partner: None Other support: None

Jennifer Chan

United States of America
MD, MPH
Date | Session | Role

5 March | Session 1 | Speaker
Discipline
Oncology
Institution
Dana-Farber Cancer Institute / Harvard Medical School
Position
Institute Physician / Associate Professor of Medicine
Main Interest
  • Clinical trials in Neuroendocrine Tumors and Neuroendocrine Carcinomas
  • Tumor microenvironment
Receipt of grants/research support: Lilly Receipt of honoraria or consultation fees: Sanofi, Boehringer Ingelheim, Ipsen, Lantheus, Curium, Novartis Stock stakeholder: Merck Spouse/partner: Pfizer Other support: Camurus (clinical trial steering committee member)

Yasmin Chotai de Lima

United Kingdom
M.Sc, RD
Date | Session | Role

6 March | Session 6B | Moderator
Discipline
Dietitian
Institution
Royal Free Hospital
Position
Clinical Lead Dietitian
Main Interest
  • Interested in nutrition and NETs. Currently working on collaboration with other Specialist Dietitians producing guidance on nutrition and NETs.
  • Mauro Cives

Mauro Cives

Italy
MD
Date | Session | Role

4 March | BS – Session 4 | Moderator
Discipline
Oncology
Institution
University of Bari "Aldo Moro"
Position
Associate Professor
Main Interest
  • Genomics of NENs
  • Adoptive T cell therapies
  • NEN clinical trials
Receipt of grants/research supports: Harbour BioMed, Advanz Pharma Receipt of honoraria or consultation fees: Ipsen, AAA – Novartis, Advanz Pharma, Harpoon Therapeutics, Harbour BioMed, Esteve, MSD, Istituto Gentili Participation in a company sponsored speaker’s bureau: Ipsen, AAA – Novartis, Advanz Pharma, Esteve
  • Anne Couvelard

Anne Couvelard

France 
MD, PhD
Date | Session | Role

4 March | BS – Session 3 | Moderator
Discipline
Pathology
Institution
AP-HP and Université Paris Cité
Position
Professor
Main Interest
  • Pathological and molecular characteristics of high grade neuroendocrine neoplasms
  • Molecular heterogeneity of neuroendocrine neoplasms
  • Diagnostic, prognostic and theranostic biomarkers in neuroendocrine neoplasms

Adina Croitoru

Romania
Prof Dr
Date | Session | Role

4 March | PG – Session D | Speaker
Discipline
Oncology
Institution
Fundeni Clinical Institute, Carol Davila University of General Medicine and Pharmacy, Bucharest, Romania
Position
Head of Department
Main Interest
  • Pancreatic Adenocarcinoma and Clonal Hematopoiesis
  • Gastrointestinal Neuroendocrine Tumors - Registry
  • Gastric Adenocarcinoma
Grants/research support:BMS,Amgen, Astellas Pharma, Merck, MSD, Roche Honoraria or/and consultation fee:Ipsen, MSD Oncology, BMS, Servier, Genesis, AstraZeneca, Amgen, Nutricia, Nestle
  • Jérôme Cros

Jérôme Cros

France 
Pr
Date | Session | Role

4 March | BS - Session 1 | Moderator
5 March | Session 5 | Speaker
Discipline
Pathology
Institution
Université Paris Cité - Hôpital Beaujon
Position
Professor
Main Interest
  • Neuroendocrine tumor molecular heterogeneity
  • Biomarkers

Meredith Cummins

Australia 
Grad Cert Oncology Grad Dip Business
Date | Session | Role

5 March | Session 4B | Moderator
Discipline
Nurse
Institution
NeuroEndocrine Cancer Australia
Position
CEO
Main Interest
  • Ensure education and awareness of NETs by HCPs is increased
  • Ongoing research is available in all countries especially Australia.

Talya Dayton

Spain
PhD
Date | Session | Role

6 March | Session 7 | Speaker
Discipline
Tumor & Cell Biology
Institution
European Molecular Biology Laboratory (EMBL), Barcelona
Position
Group Leader
Main Interest
  • Wouter De Herder

Wouter W. de Herder

Netherlands
MD PhD
Date | Session | Role

6 March | Session 7 | Moderator
Discipline
Endocrinology
Institution
Erasmus MC & Erasmus MC Cancer Center, ENETS CoE, Rotterdam
Position
Professor of Endocrine Oncology
Main Interest
  • Fibrosis and NET
  • PRRT
  • Therapy of NET
Receipt of honoraria or consultation fees: Ipsen, AAA-Novartis, ITM, Camurus Participation in a company sponsored speaker's bureau: Ipsen, AAA-Novatis, Recordati

Louis de Mestier

France 
Professor, MD, PhD
Date | Session | Role

4 March | BS – Session 2 | Speaker
Discipline
Gastroenterology
Institution
Beaujon Hospital, Université Paris-Cité, Clichy
Position
Full Professor
Main Interest
  • Predictive and theranostic biomarkers in neuroendocrine tumors
  • Clinicopathological and molecular characterization of tumor heterogeneity in neuroendocrine tumors
  • Inherited predispositions to digestive neuroendocrine tumors
I have the following potential conflict of interest to report: - Receipt of grants/research supports: Esteve, Boehringer-Ingelheim - Receipt of honoraria or consultation fees: Novartis, Ipsen, Boerhinger-Ingelheim, Esteve, Servier, Mayoly, Viatris
  • Maribel del Olmo

Maribel Del Olmo Garcia

Spain
MD PhD
Date | Session | Role

4 March | PG – Session B | Speaker
Discipline
Endocrinology
Institution
University and Polytechnic Hospital La Fe
Position
Consultant in Endocrinology and Nutrition
Main Interest

Rachael Delderfield

United Kingdom
PG Dip
Date | Session | Role

6 March | Session 6B | Speaker
Discipline
Nurse
Institution
University Hospital Bristol and Weston NHS Foundation Trust
Position
Neuroendocrine Cancer Clinical Nurse Specialist
Main Interest

Timm Denecke

Germany
Prof. Dr. med.
Date | Session | Role

4 March | PG – Session B | Speaker

4 March | PG – Session D | Panellist
Discipline
Radiology
Institution
Universitätsklinikum Leipzig
Position
Head of Radiology
Main Interest
  • Oncologic Imaging includingRadiology and Nuclear Medicine
  • Interventional Oncology
  • Neuroendocrine Tumors
Honoraria and travel expenses as guest speaker, advisory board meetings, expert opinions: Bayer, Astra Zeneca, Parexel/Calyx, MSD, Roche, IPSEN, Novartis, AAA, Siemens

Christophe Deroose

Belgium
M.D, Ph.D.
Date | Session | Role

6 March | Session 6A | Speaker
Discipline
Nuclear Medicine
Institution
KU Leuven
Position
Full Professor
Main Interest
  • PRRT
  • Somatostatin receptor PET
  • MFBG PET
CMD is an employee of UZ Leuven. He is/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, IRE, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy, Telix and ITM. His institution has received travel fees from: GE Healthcare, Sirtex.

Lawrence Dierickx

France 
PhD MD
Date | Session | Role

4 March | PG – Session A | Speaker

4 March | PG – Session D | Panellist
Discipline
Nuclear Medicine
Institution
University of Toulouse, Oncopole Claudius Regaud, Intstitut Universitaire Cancer Toulouse Oncopole
Position
MD
Main Interest
  • Pharmaco-kinetic and -dynamic Profile of 177Lu DOTATATE for Treatment of Neuroendocrine Tumors.
  • Optimisation of Theranostic Approach for Neuroendocrine Tumors
  • Nuclear Andrology
Transport to congres : NOVARTIS, AAA, IPSEN, ADVANZ PHARMA Invited speaker : AAA, ADVANZ PHARMA
  • Clarisse Dromain

Clarisse Dromain

Switzerland
Full Professor
Date | Session | Role

4 March | PG – Session A | Moderator & Speaker
Discipline
Radiology
Institution
Lausanne University Hospital and University of Lausanne
Position
Head of Oncologic and Digestive Imaging
Main Interest
  • Imaging of neuroendocrine tumor

Rafael Duran

Switzerland
Date | Session | Role

6 March | Session 5A | Speaker
Discipline
Radiology
Institution
CHUV - Lausanne - Interventional Radiology
Position
Head of Interventional Radiology
Main Interest
  • Liver-directed locoregional therapies
  • Interventional radiology
  • Minimally invasive therapies
I have the following potential conflict of interest to report: Consultant for and recipient of grant support from Boston Scientific/BTG, Guerbet, Siemens. Recipient of grant support from Society of Interventional Oncology. Consultant for AstraZeneca.
  • Prof. Massimo Falconi

Massimo Falconi

Italy
Prof. Falconi
Date | Session | Role

5 March | Session 2B | Moderator
Discipline
Surgery
Institution
"Vita e Salute" University, IRCCS San Raffaele Hospital
Position
Full Professor of Surgery
Main Interest
  • Pancreatic and Transplant Surgery
  • Neuroendocrine GEP NEN
  • Pancreatic ductal adenocarcinoma

Nicola Fazio

Italy
M.D., Ph.D.
Date | Session | Role

5 March | Session 3A | Moderator
Discipline
Oncology
Institution
European Institute of Oncology
Position
Director of Division and Program
Main Interest
  • Neuroendocrine neoplasms
  • Upper GI cancers
  • Hepato-pancreato-biliary cancers
Receipt of grants/research support: Merck, Esteve Receipt of honoraria or consultation fees: Astellas, AstraZeneca, Ipsen, Novartis, ITM, Esteve, Recordati, MSD

Wolfgang Fendler

Germany
MD
Date | Session | Role

6 March | Session 6A | Speaker
Discipline
Nuclear Medicine
Institution
University Hospital Essen
Position
Vice Chair
Main Interest
SOFIE Bioscience (research funding), Janssen/JJ (consultant, speaker), Perceptive (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant, research funding), Telix (speaker, research funding), GE Healthcare (speaker, consultant), Eczacıbaşı Monrol (speaker), Abx (speaker), Amgen (speaker, research funding), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding), Curium (consultant).

Julia Fricke

Switzerland
MD
Date | Session | Role

6 March | Session 6A | Speaker
Discipline
Nuclear Medicine
Institution
Department of Nuclear Medicine, University Hospital Basel
Position
Physician
Main Interest

Rocio Garcia-Carbonero

Spain
MD, PhD
Date | Session | Role

5 March | Session 1 | Moderator

5 March | LAA | Moderator

5 March | Session 4B | Moderator

6 March | Session 7 | Moderator

6 March | Awards Ceremony | Moderator
Discipline
Oncology
Institution
Hospital Universitario 12 de Octubre, Universidad Complutense of Madrid
Position
Head, GI and NE Oncology Unit, Oncology Department & Associate Professor of Medicine
Main Interest
  • New drug development in NETs and NECs
  • Development of biomarkers in NENs
  • Translational research
I have received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: AAA-Novartis, Advanz Pharma, Astellas, Bayer, BMS, Boerhinger, Crinetics, Esteve, GSK, Hutchmed, Ipsen, ITM, MSD, PharmaMar, Pierre Fabre, Sanofi, Servier, Takeda. I have received funding for investigator-initiated trials from BMS, MSD and CRIS Foundation My spouse has received honoraria for for speaker engagements or advisory roles from Amgen, Astra Zeneca, Celgene, Genomica, Gilead, Janssen, Lilly, Merck, Roche, Sysmex.

Wanda Geilvoet

Netherlands
Date | Session | Role

6 March | Session 6B | Speaker
Discipline
Nurse
Institution
Erasmus MC, Rotterdam, The Netherlands
Position
Nurse Practitioner, Endocrinology
Main Interest
  • Outpatient clinic for patients with neuroendocrine tumors and (malignant) adrenal tumors, patient coordinator and contact person for patients
  • Active member tumor board for endocrine tumors and coordinator for the ENETS Center of Excellence key figures and audits in Erasmus MC
  • Vice-chair of ENETS Nurse & Dietician Group

Benjamin Gibert

France 
Date | Session | Role

4 March | BS – Session 1 | Speaker
Discipline
Oncology
Institution
Cancer Research Centre of Lyon (CRCL)
Position
Director of the Gastroenterology and Technologies for Health Team
Main Interest
  • Small inestinal NETs orgin
  • Characterization of new PRRT metals
I have the following potential conflict of interest to report: Receipt of honoraria or consultation fees from Netris Pharma (France)
  • Simona Glasberg

Simona Glasberg

Israel
Professor
Date | Session | Role

4 March | PG – Session A | Moderator
Discipline
Endocrinology
Institution
Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel
Position
Associate Professor of Medicine, Head of Neuroendocrine Tumor Unit, ENETS Center of Excellence, Division of Medicine
Main Interest
  • Enhancers and neuroendocrine neoplasms
  • Modulation of endocannabinoid system in neuroendocrine neoplasms
  • Theranostic in neuroendocrine neoplasms

Ashley Grossman

United Kingdom
FMedSci
Date | Session | Role

5 March | LAA | Recipient

5 March | Poster Stage 1 | Moderator
Discipline
Endocrinology
Institution
Royal Free London
Position
Professor of Endocrinology
Main Interest
  • Genetic endocrine tumours
  • Phaeochromocytomas & paragangliomas
  • Pituitary neuroendocrine tumours
  • Julien HADOUX

Julien Hadoux

France 
MD, PhD
Date | Session | Role

5 March | Session 2A | Speaker
Discipline
Oncology
Institution
Gustave Roussy
Position
Attending Physician
Main Interest
  • Neuroendocrine carcinoma
  • Precision medicine
  • Anaplastic thyroid carcinoma
Personal financial interests: Consultancy or advisory role: Roche, Lilly, IPSEN, Pharma Mar, AAA , EISAI, Bayer, ITM, Novartis Congress attendance and travel: IPSEN, AAA, Roche Speaker, leadership roles, stock ownership, licensing fees or royalties: None Research funding: Novartis, Sanofi, Lilly Institutional financial interests: Lilly, EISAI Non-financial interests: ENDOCAN (Endocrine cancers) network in France

Thorvardur Halfdanarson

United States of America
M.D.
Date | Session | Role

5 March | Session 4B | Speaker
Discipline
Oncology
Institution
Mayo Clinic, Rochester, Minnesota
Position
Professor of Oncology
Main Interest
  • Theragnostics in the management of patients with neuroendocrine neoplasms
  • Epidemiology of neuroendocrine neoplasms
  • Novel therapy for patients with neuroendocrine neoplasms
Research support to institution: Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, ITM Isotopen Technologien Muenchen, Perspective Therapeutics, Rezolute Consulting/Advisory Board (*personal compensation): Exelixis*, Curium*, Boehringer-Ingelheim*, Biomea Fusion*, Sanofi*, Novartis, ITM Isotopen Technologien Muenchen, Crinetics, Perspective Therapeutics, Camurus, Abdera Therapeutics

Hans Hofland

Netherlands
PhD
Date | Session | Role

4 March | PG – Session D | Speaker &  Panellist
Discipline
Endocrinology
Institution
Erasmus MC
Position
Endocrinologist, Head of ENETS Center of Excellence
Main Interest
  • Functional NET syndromes
  • Radionuclide therapy
Receipt of honoraria or consultation fees: Novartis, Ipsen, Serb

Peter Igaz

Hungary
MD PhD DSc
Date | Session | Role

5 March | Session 2A | Moderator
Discipline
Endocrinology
Institution
Semmelweis University, Faculty of Medicine, Department of Endocrinology
Position
Department Head, Full Professor of Medicine and Endocrinology
Main Interest
  • Studies on non-coding RNA, tissue and circulating microRNA as biomarkers of malignancy and follow-up markers of endocrine tumors (GEP-NET and adrenal)
  • Circulating microRNAs in primary aldosteronism for differentiating uni- and bilateral forms
  • Endocrine tumor syndromes
I have the following potential conflict of interest to report: Receipt of grants/research support: - Receipt of honoraria or consultation fees: Ipsen Pharma, Novartis, Astra-Zeneca, NovoNordisk, Eli-Lilly, Recordati Participation in a company sponsored speaker’s bureau:- Stock stakeholder:- Spouse/partner:-

Louise Izatt

United Kingdom
Ma MB BChir FRCP PhD
Date | Session | Role

5 March | Session 2A | Speaker
Discipline
Clinical Genetics
Institution
Guy's and St Thomas NHS Foundation Trust London, UK
Position
Consultant and Honorary Senior Lecturer
Main Interest
  • Endocrine tumours
  • Cancer Genetics
  • Hereditary breast and ovarian cancer

Moritz Jesinghaus

Germany
Prof. Dr. med.
Date | Session | Role

4 March | BS – Session 4 | Speaker
Discipline
Pathology
Institution
Institute of Pathology, University Hospital Marburg, Germany
Position
Professor / Senior Physician
Main Interest
  • Tumor heterogeneity
  • Neuroendocrine Neoplasms
  • AI
  • Gregory Kaltsas

Gregory Kaltsas

Greece
Professor
Date | Session | Role

4 March | BS – Session 2 & 3 | Moderator

5 March | LAA | Laudator
Discipline
Endocrinology
Institution
National and Kapodistrian University of Athens, Greece
Position
Professor
Main Interest
  • Inherited Endocrine Syndromes
  • Appendiceal neuroendocrien neoplasms
  • Gastric Neuroendocrine neoplasms
Grants/Research : IPSEN, RECORDATI, NOVO, BIOKOSMOS Honoraria: IPSEN, RECORDATI, NOVO
  • Andreas Kjaer

Andreas Kjaer

Denmark
MD, PhD
Date | Session | Role

6 March | Session 6A | Moderator
Discipline
Nuclear Medicine
Institution
Rigshospitalet & University of Copenhagen
Position
Professor, Chief Physician
Main Interest
  • Molecular imaging of neuroendocrine tumors
  • Theranostics and targeted radionuclide therapy in NET

Teodora Kolarova

Bulgaria
Ms
Date | Session | Role

5 March | Session 4B | Speaker
Discipline
Patient / Patient Advocate
Institution
International Neuroendocrine Cancer Alliance
Position
Executive Director
Main Interest
  • Improving understanding of NENs - Think NENs Global Educational Program for Primary Care Physicians
  • Improving access to optimal diagnostics and treatment for NEN patients - SCAN Global Survey
  • Raising awareness about NENs far and wide - NET Cancer Day
  • Beata Kos-Kudła

Beata Kos-Kudła

Poland
MD, PhD, Prof.
Date | Session | Role

5 March | Session 4A | Speaker

5 March | Session 5B | Moderator
Discipline
Endocrinology
Institution
Medical University of Silesia, Dept. of Endocrinology and Neuroendocrine Tumors
Position
Professor, Chair of the Department
Main Interest
  • Biomarkers in NET
  • Diagnosis and treatment of GEP NET
  • Lung NET
Receipt of grants/research supports: no Receipt of honoraria or consultation fees: Merck, Ipsen, Novartis, Pfizer. Participation in a company sponsored speaker’s bureau: Merck, IBSA, Ipsen, Novartis, Pfizer. Stock shareholder: no Spouse/partner: no Other support (please specify): no
  • Anna Koumarianou

Anna Koumarianou

Greece
MD PhD
Date | Session | Role

5 March | Session 3A | Speaker
Discipline
Oncology
Institution
Fourth Department of Internal Medicine, National and Kapodistrian University of Athens Greece
Position
Head of Hematology Oncology Unit
Main Interest
  • Lung Neuroendocrine Tumors
  • miRNA biomarkers
  • Clinical Trials in high-grade tumors
Receipt of grants/research supports: GENFLEET, BMS, MSD, ASTRAZENECA Receipt of honoraria or consultation fees: ASTRAZENECA, GILEAD Participation in a company sponsored speaker’s bureau: BMS, ASTRAZENECA

Michael Kühn

Germany
Professor Dr. med.
Date | Session | Role

4 March | BS – Session 3 | Speaker
Discipline
Oncology
Institution
University Medical Center, Johannes Gutenberg-University Mainz
Position
Chief Leukemia Service, Attending Physician
Main Interest
  • Epigeneitic dependencies / The Menin-KMT2A chromatin complex in leukemia
  • Acute myeloid leukemia
  • Targeted leukemia treatment
Consultant for Pfizer, Kura Oncology, Jazz Pharmaceuticals, Bristol Myers Squibb/Celgene, AbbVie, Servier, Johnson&Johnson, Blueprint, and Daiichi Sankyo / Speaker’s bureau of Gilead / Travel support from Abbvie, Servier, Johnson&Johnson, Bristol Myers Squibb/Celgene, and Daiichi Sankyo / Research funding from Kura-Oncology and Syndax

Stefano La Rosa

Italy
Prof.
Date | Session | Role

4 March | BS – Session 1 | Speaker
Discipline
Pathology
Institution
University of Insubria
Position
Associate Professor
Main Interest
  • Pathology, neuroendocrine neoplasm diagnosis

Angela Lamarca

Spain
MD, PhD, MSc
Date | Session | Role

4 March | PG – Session C | Speaker
Discipline
Oncology
Institution
Fundacion Jimenez Diaz University Hospital
Position
Consultant Medical Oncologist
Main Interest
  • Systemic treatment for NENs
  • Development of predictive and prognostic biomarkers in NENs
  • Management of carcinoid syndrome and associated complications
Travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan, Delcath Advanz Pharma and Roche. Speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA/Novartis, QED, Servier, Astra Zeneca, EISAI, Roche, Advanz Pharma, Jazz Therapeutics and MSD. Advisory and consultancy honoraria from EISAI, Nutricia, Ipsen, QED, Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim, GENFIT, TransThera Biosciences, Taiho, MSD, JAZZ Therapeutics and Viatris. Principal Investigator-associated Institutional Funding form QED, Merck, Boehringer Ingelheim, Servier, Astra Zeneca, GenFit, Panbela Therapeutics, Novocure GmbH, Camurus AB, Albireo Pharma, Taiho, TransThera, Jazz Therapeutics, Roche and Novartis. Member of the Knowledge Network and NETConnect Initiatives funded by Ipsen.
  • Ilaria Marinoni

Ilaria Marinoni

Switzerland
PhD
Date | Session | Role

4 March | BS – Session 3 | Moderator

6 March | Session 5A | Speaker
Discipline
Tumor & Cell Biology
Institution
Institute of Tissue Medicine and Pathology
Position
Group Leader
Main Interest
  • Studying epigenetic changes occurring along Pancreatic Neuroendocrine Tumor progression.
  • Establishing an in vitro model of PanNET for precision medicine

Wendy Martin

United Kingdom
MSc, BSc (hons), RGN
Date | Session | Role

6 March | Session 6B | Speaker
Discipline
Nurse
Institution
Kings College Hospital Foundation Trust. UK
Position
Lead NET Clinical Nurse Specialist
Main Interest
  • Quality of Life
  • Carcinoid heart disease
  • Education
Novartis - Speaker at educational event Ipsen - Honoraria/consultation fees SERB - Advisory Board Member
  • Mairead McNamara

Mairéad McNamara

United Kingdom
MB PhD
Date | Session | Role

4 March | PG – Session D | Moderator
Discipline
Oncology
Institution
University of Manchester / The Christie
Position
Senior Lecturer / Honorary Consultant
Main Interest
  • CI for NET-02: A randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
  • Clinical supervisor for PhD: DISSECTING THE NEUROENDOCRINE LANDSCAPE OF EXTRA-PULMONARY NEUROENDOCRINE CARCINOMA TO DISCOVER BIOMARKERS WITH CLINICAL UTILITY
  • Methylation analysis of samples from NET-02
Research support: Astra Zeneca and Ipsen Speaker bureau: Astra Zeneca Travel/Accommodation: AAA (Novartis)

Massimo Milione

Italy
MD, PhD
Date | Session | Role

4 March | PG – Session A | Speaker
Discipline
Pathology
Institution
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Position
Director of 1st Pathology Division
Main Interest
  • Gastroenteropancreatic neuroendocrine neoplasms (NET-NEC)
  • Lung neuroendocrine tumors and carcinomas
  • NET-NEC molecular analysis

Axel Mosig

Germany
PhD
Date | Session | Role

4 March | BS - Session 1 | Speaker
Discipline
Bioinformatics
Institution
Ruhr University Bochum
Position
Professor
Main Interest
  • Biomedical Image Analysis
  • Quantitative Microscopy
  • Computational Pathology

Els Nieveen van Dijkum

Netherlands
Prof Dr
Date | Session | Role

6 March | Session 5A | Moderator
Discipline
Surgery
Institution
Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, The Netherlands
Position
Chair ENETS COE Amsterdam UMC
Main Interest
  • Pancreatic NET - Risk stratification for recurrence, wait and see in small pNET, surgical outcomes and Quality of Life
  • Small bowel NET - Surgical approach, fluorescence, treatment planning
  • Training and education - Training residents and surgeons, nurses and patients
  • Dermot O'Toole

Dermot O'Toole

Ireland
MD
Date | Session | Role

4 March | PG – Session B | Moderator
Discipline
Gastroenterology
Institution
St Vincent’s University & St James Hospitals & Trinity College, Dublin
Position
Professor in Gastroenterology & National Clinical Lead in NET
Main Interest
  • Digestive neuroendocrine tumours
  • Barrett's oesophagus (Dx and treatment)
  • Familial pancreatic cancer

Karel Pacak

Czech Republic
Date | Session | Role

5 March | Session 2A | Speaker
Discipline
Endocrinology
Institution
AKESO, Prague, Czech Republic & NICHD/NIH, Bethesda, USA
Position
Medical Director
Main Interest
  • Pheochromocytoma, paraganglioma
  • Adrenal tumors
  • Endocrine imaging
  • Francesco Panzuto

Francesco Panzuto

Italy
MD, PhD
Date | Session | Role

4 March | PG – Session B | Speaker
Discipline
Gastroenterology
Institution
Sant'Andrea University Hospital, Rome, Italy
Position
Associate Professor of Gastroenterology, Sapienza University of Rome, Digestive Disease Unit, Coordinator ENETS Center of Excellence of Rome (Sant'Andrea site)
Main Interest
  • Gastric Neuroendocrine Neoplasia
  • NEN epidemiology (national registry - database)
  • Prognostic features and risk factros for NEN progression

Stefano Partelli

Italy
Prof
Date | Session | Role

6 March | Session 5A | Moderator
Discipline
Surgery
Institution
Vita-Salute San Raffaele University
Position
Associate Professor of Surgery
Main Interest
  • Surgical treatment of GEP-NEN
  • Management of asymptomatic small Pan-NET
  • Preoperative therapy for advanced GEP-NEN
  • Andreas Pascher

Andreas Pascher

Germany
MD, PhD
Date | Session | Role

4 March | PG – Session B | Moderator
Discipline
Surgery
Institution
UKM Muenster, Dept. of General, Visceral and Transplant Surgery
Position
Professor of Surgery, Head of Department
Main Interest
  • MJC EBNEN
  • Liver Surgery for NEN liver metastasis
  • GI NEN
  • Marianne Ellen Pavel

Marianne Pavel

Germany
Prof. Dr.
Date | Session | Role

5 March | Session 1 | Moderator
Discipline
Endocrinology
Institution
Universitätsklinikum Erlangen
Position
Senior Physician and Chair of Endocrinology
Main Interest
  • Precision oncology in NEN
  • Novel targeted treatment in NEN
  • High grade NEC

Fedro Peccatori

Italy
Dr
Date | Session | Role

5 March | Session 4A | Speaker
Discipline
Oncology
Institution
European Institute of Oncology
Position
Director Fertility and Procreation Unit
Main Interest
  • Cancer in Pregnancy
  • Fertility in Oncology

Marc Peeters

Belgium
PhD
Date | Session | Role

4 March | BS – Session 3 | Speaker
Discipline
Oncology
Institution
Antwerp University
Position
Full Professor
Main Interest
  • Biomarkers
  • Data
  • Patient's well being

Danielle Ralic

Switzerland
Date | Session | Role

5 March | Session 4B | Speaker
Discipline
Technology
Institution
Ancora.ai AG
Position
CEO
Main Interest
  • AI
  • Health Equity
  • Clinical Research
Stock stakeholder: Ancora.ai

John Ramage

United Kingdom
Professor
Date | Session | Role

5 March | Session 3A | Speaker
Discipline
Gastroenterology
Institution
King's Health Partners and Hampshire Hospitals Foundation Trust
Position
Consultant Gastroenterologist and Hepatologist
Main Interest
  • Quality of life and symptoms scores in neuroendocrine tumours of the small bowel and liver
  • Rectal NET endoscopic therapy
  • UK NET registry data epidemiology
Speaker at international conference sponsored by IPSEN Fees for speaker for internal education at IPSEN

Rachel Riechelmann

Brazil
Dr
Date | Session | Role

5 March | Session 4A | Speaker

5 March | Session 5B | Moderator
Discipline
Oncology
Institution
AC Camargo Cancer Center
Position
Head of the Clinical Oncology Department
Main Interest
  • Clinical trials of NET
  • Carcinoid syndrome
  • High grade NEN
Consultancy fees and lectures: Ipsen and Exelixis Research grant: Servier

Anja Rinke

Germany
Prof Dr
Date | Session | Role

4 March | PG – Session D | Moderator
Discipline
Gastroenterology
Institution
UKGM, Marburg / Philipps University Marburg
Position
Consultant
Main Interest
  • GEP NEN, clinical trials, prognostic parameters
  • Lung NETs
Receipt of grants/research support: ITM Solution, Ipsen, Novartis Receipt of honoraria or consultation fees: Noavrtis, Ipsen, AstraZeneca, Falk, MCI, Serb, Esteve, derCampus

Ramon Salazar

Spain
MD, PhD
Date | Session | Role

5 March | Session 3B | Moderator
Discipline
Oncology
Institution
Institut Catala d'Oncologia
Position
Head of Medical Oncology Department
Main Interest
  • SEQTOR Clinical Trial
  • SEQTOR Aancilliary Studies
  • Biomarkers & new molecular therapeutics
Receipt of honoraria or consultation fees: Takeda Participation in a company sponsored speaker’s bureau: Esteve, Novartis, Ipsen

Ana Paula Santos

Portugal
PhD
Date | Session | Role

5 March | Session 4A | Moderator
Discipline
Endocrinology
Institution
Porto Portuguese Institute of Oncology (IPO Porto / Porto Comprehensive Cancer Center (P.CCC)
Position
Endocrinology Consultant
Main Interest
  • Neuroendocrine Tumors
  • Metabolic Syndrome and Cancer
  • Association between Obesity and MetS with Neuroendocrine Tumors

Alain Sauvanet

France 
Pr
Date | Session | Role

6 March | Session 5A | Speaker
Discipline
Surgery
Institution
Department of HPB Surgery, Hospital Beaujon, APHP, Unviversity Paris Cité
Position
Clinician
Main Interest
  • Pan NET
  • Pancreatic neoplasm
  • Pancreatic Surgery

Ramesh Shivdasani

United States of America
Professor
Date | Session | Role

4 March | BS – Keynote Speech | Speaker
Discipline
Tumor & Cell Biology
Institution
Dana-Farber Cancer Institute and Harvard Medical School
Position
Professor
Main Interest
  • Neuroendocrine cell differentiation
  • Transcriptional and epigenetic control mechanisms
  • Intestinal stem cell biology
  • Simron SINGH

Simron Singh

Canada
Dr
Date | Session | Role

6 March | Session 5A | Speaker
Discipline
Oncology
Institution
University of Toronto, Susan Leslie Clinic for Neuroendocrine Cancer
Position
Professor or Medicine
Main Interest
  • Clinical Trials
  • Patient Centered Care
  • Health Services Reserach
  • Halfdan Sorbye

Halfdan Sorbye

Norway
Professor
Date | Session | Role

4 March | BS – Session 4 | Moderator
Discipline
Oncology
Institution
Cancer Clinic, Haukeland University Hospital, Bergen, Norway
Position
Professor
Main Interest
  • Digestive Neuroendocrine Carcinoma (NEC)
  • NET G3
I have the following potential conflict of interest to report: Receipt of honoraria or consultation fees: Boehringer Ingelheim, Ipsen, Novartis, ITM, MSD, AAA, Pierre Fabre, Daiichi Sankyo,

Francesca Spada

Italy
M.D., Ph.D
Date | Session | Role

4 March | PG – Session C | Moderator & Speaker
Discipline
Oncology
Institution
European Institute of Oncology (IEO), IRCCS, Milan, Italy
Position
High Specialized Medical Oncologist (M.D., Ph.D) for Neuroendocrine Neoplasms, Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors
Main Interest
  • Management of high grade NENs and mixed NENs
  • Chemotherapy in NENs
  • Management of functioning NETs
Receipt of grants/research supports: Novartis, Ipsen, Esteve Receipt of honoraria or consultation fees: Novartis, Ipsen, Esteve Other support: Coordinator of AIOM NEN Guidelines
  • Raj Srirajaskanthan

Raj Srirajaskanthan

United Kingdom
Professor
Date | Session | Role

5 March | Session 4B | Speaker
Discipline
Gastroenterology
Institution
Kings College Hospital, London
Position
Consultant Gastroenterologist
Main Interest
  • Epidemiology and prognosis of Neuroendocrine Neoplasms
  • Endoscopic characterisation of resection of NETs
  • Digital technology and integration to healthcare
  • Margot Tesselaar

Margot Tesselaar

Netherlands
MD PhD
Date | Session | Role

5 March | Session 3A | Moderator
Discipline
Oncology
Institution
Netherlands Cancer Institute
Position
Head of Department of Gastrointestinal Oncology
Main Interest
  • Immunotherapy/chemotherapy
  • NEC/MCC
  • Carcinoid heart disease

Chrissie Thirlwell

United Kingdom
MD PhD
Date | Session | Role

5 March | Session 3B | Moderator
Discipline
Oncology
Institution
University of Bristol
Position
Professor of Cancer Genomics
Main Interest
  • Integrated genomic analysis of neuroendocrine neoplasms
  • Epigenetics - DNA methylation
  • Molecular classification of neuroendocrine neoplasms
Co-Director Blackdown Consultancy
  • Eva Tiensuu Janson

Eva Tiensuu Janson

Sweden
MD PhD
Date | Session | Role

5 March | Session 2B | Moderator
Discipline
Endocrinology
Institution
Dept. of Medical Sciences, Uppsala University
Position
Professor
Main Interest
  • Small intestinal NETS
  • Neuroendocrine carcinomas
  • Genetics

Christos Toumpanakis

United Kingdom
Professor
Date | Session | Role

5 March | PG – Session A | Speaker
Discipline
Gastroenterology
Institution
NET Unit Royal Free Hospital London
Position
Professor of Gastroenterology and NETs - University College of London
Main Interest
  • Carcinoid Heart Disease
  • Novel blood and imaging biomarkers
  • Mesenteric fibrosis
Receipt of grants/research support: IPSEN, NOVARTIS Receipt of honoraria or consultation fees: IPSEN, NOVARTIS Participation in a company sponsored speaker’s bureau: IPSEN, NOVARTIS

Marina Tsoli

Greece
MD, PhD
Date | Session | Role

4 March | BS – Session 2 | Speaker
Discipline
Endocrinology
Institution
EKPA-LAIKO ENETS CoE, Laiko Hospital, National and Kapodistrian University of Athens, Greece
Position
Consultant Endocrinologist
Main Interest
  • Neuroendocrine tumors
  • Adrenal Tumors
  • Endocrine familial syndromes
I have the following potential conflict of interest to report: Receipt of honoraria or consultation fees: IPSEN

Silvia Uccella

Italy
MD, PhD
Date | Session | Role

4 March | BS – Session 1 | Moderator
Discipline
Pathology
Institution
Humanitas University and IRCCS Humanitas Research Hospital
Position
Full Professor / Head of Pathology Department
Main Interest
  • Diagnostic, prognostic, and predictive features of neuroendcorine neoplasms
  • Microbiota in neureodncorine neoplasms
  • Molecular features of neuroendocrine neoplasms

Sanne van der Stelt

Netherlands
Date | Session | Role

6 March | Session 6B | Speaker
Discipline
Endocrinology
Institution
Erasmus Medical Center
Position
Nurse Practitioner
Main Interest
  • Peptide Receptor Radionuclide Therapy

Rachel van Leeuwaarde

Netherlands
MD, PhD
Date | Session | Role

4 March | BS – Session 2 | Speaker
Discipline
Endocrinology
Institution
University Medical Center Utrecht
Position
Senior Staff
Main Interest
  • NET epidemiology: the effect of lifestyle factors and NET in a large international cohort study
  • Von Hippel Lindau's disease - a prospective nationwide registry
  • NET prospective data and biobank study - FORCE-NEN

Bernadette van Nesselrooij

Netherlands
MSc
Date | Session | Role

5 March | Session 4A | Speaker
Discipline
Clinical Genetics
Institution
UMC Utrecht
Position
Clinical Geneticist, Member of Staff
Main Interest
  • Member of the expertise centra in the University Medical Center Utrecht ENETS (UMC Utrecht together with NKI/AVL Amsterdam), MEN syndromes, VHL syndrome and hereditary paraganglioma pheochromocytoma
  • Oncogenetics in general (patient care)

Timon Vandamme

Belgium
MD PhD
Date | Session | Role

6 March | Session 7 | Speaker
Discipline
Oncology
Institution
University Hospital Antwerp
Position
Senior Consultant - Assistant Professor
Main Interest
  • Circulating cell-free DNA
  • Cellular therapies including mRNA vaccinatie, CAR-T and CAR-NK
  • (Epi)genomics
Consultancy, advisory roles, honoraria from AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Incyte, Ipsen, MyNeoTx, MSD, Nordic Pharma, Novartis, Roche, Sirtex, Servier, Takeda. Research funding (institutional) from Ipsen and Novartis. Support for travel/accomodation from Ipsen, AstraZeneca, Roche and Servier.

Marco Volante

Italy
MD, PhD
Date | Session | Role

4 March | BS – Session 4 | Speaker
Discipline
Pathology
Institution
Department of Oncology, University of Turin
Position
Full Professor
Main Interest
  • Lung neuroendocrine neoplasms
  • Molecular pathology of NEN
  • Mixed/combine non-NE / NE neoplasms

Thomas Walter

France 
PhD, MD
Date | Session | Role

5 March | Session 1 | Speaker
Discipline
Gastroenterology
Institution
Hospices Civils of Lyon
Position
Professor
Main Interest
  • Systemic treatments of NEN
  • Leading some clinical trials (NIPINEC, BEVANEC, MGMT-NET...)
  • Metastatic lung carcinoid tumors
I have the following potential conflict of interest to report: -Receipt of grants/research support: Gilead for my institution (for REWENEC and ImmunoRare studies -Receipt of honoraria or consultation fees: Novartis, IPSEN, Boerhinger, Pierre Fabre.

Maria Wedin

Sweden
MD, PhD
Date | Session | Role

4 March | PG – Session B | Speaker
Discipline
Surgery
Institution
Örebro University
Position
PhD
Main Interest
  • Metastatic pattern in Si-NET and pan-NET
  • Impact of Bone Metastases in Si-NET patients
  • Serum 5 HIAA

Staffan Welin

Sweden
MD, PhD
Date | Session | Role

4 March | PG – Session C | Speaker
Discipline
Endocrinology
Institution
Endocrine Oncology Uppsala
Position
Head of Department
Main Interest
  • PRRT
  • GEPNETS
  • MEN1

Wendy Wolters

Netherlands
MSc
Date | Session | Role

4 March | PG – Session D | Panellist

6 March | Session 6B | Moderator
Discipline
Oncology
Institution
Antoni van Leeuwenhoek, Amsterdam & UMC Utrecht
Position
Nurse Practitioner
Main Interest
  • Neuro-endocrien tumors
  • Neuro-endocrine carcinomas
  • Von Hippel Lindau disease

Maria Chiara Zatelli

Italy
Professor
Date | Session | Role

5 March | Session 1 | Speaker
Discipline
Endocrinology
Institution
University of Ferrara
Position
Professor
Main Interest
  • Endocrine oncology
  • Prognostic markers in neuroendocrine tumors
  • Diagnostic tools of thyroid nodules

Georgios Zografos

Greece
MD, PhD
Date | Session | Role

5 March | Session 2A | Speaker
Discipline
Surgery
Institution
Athens General Hospital, Athens
Position
Chairman, Department of Surgery
Main Interest
  • Endocrine surgery
  • Laparoscopic surgery